130 related articles for article (PubMed ID: 22336998)
1. Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma.
Sopo M; Anttila M; Sallinen H; Tuppurainen L; Laurema A; Laidinen S; Hamalainen K; Tuunanen P; Koponen JK; Kosma VM; Heinonen S; Alitalo K; Yla-Herttuala S
Int J Cancer; 2012 Nov; 131(10):2394-401. PubMed ID: 22336998
[TBL] [Abstract][Full Text] [Related]
2. Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice.
Sallinen H; Anttila M; Gröhn O; Koponen J; Hämäläinen K; Kholova I; Kosma VM; Heinonen S; Alitalo K; Ylä-Herttuala S
Cancer Gene Ther; 2011 Feb; 18(2):100-9. PubMed ID: 20865022
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice.
Sallinen H; Anttila M; Narvainen J; Koponen J; Hamalainen K; Kholova I; Heikura T; Toivanen P; Kosma VM; Heinonen S; Alitalo K; Yla-Herttuala S
Mol Ther; 2009 Feb; 17(2):278-84. PubMed ID: 19050699
[TBL] [Abstract][Full Text] [Related]
4. Combined Gene Therapy Using AdsVEGFR2 and AdsTie2 With Chemotherapy Reduces the Growth of Human Ovarian Cancer and Formation of Ascites in Mice.
Tuppurainen L; Sallinen H; Karvonen A; Valkonen E; Laakso H; Liimatainen T; Hytönen E; Hämäläinen K; Kosma VM; Anttila M; Ylä-Herttuala S
Int J Gynecol Cancer; 2017 Jun; 27(5):879-886. PubMed ID: 28498260
[TBL] [Abstract][Full Text] [Related]
5. Preclinical safety, toxicology, and biodistribution study of adenoviral gene therapy with sVEGFR-2 and sVEGFR-3 combined with chemotherapy for ovarian cancer.
Tuppurainen L; Sallinen H; Kokki E; Koponen J; Anttila M; Pulkkinen K; Heikura T; Toivanen P; Hämäläinen K; Kosma VM; Heinonen S; Alitalo K; Ylä-Herttuala S
Hum Gene Ther Clin Dev; 2013 Mar; 24(1):29-37. PubMed ID: 23692381
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.
Hu L; Hofmann J; Zaloudek C; Ferrara N; Hamilton T; Jaffe RB
Am J Pathol; 2002 Nov; 161(5):1917-24. PubMed ID: 12414537
[TBL] [Abstract][Full Text] [Related]
7. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
Inoue K; Slaton JW; Davis DW; Hicklin DJ; McConkey DJ; Karashima T; Radinsky R; Dinney CP
Clin Cancer Res; 2000 Jul; 6(7):2635-43. PubMed ID: 10914704
[TBL] [Abstract][Full Text] [Related]
8. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
9. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
Rosanò L; Spinella F; Salani D; Di Castro V; Venuti A; Nicotra MR; Natali PG; Bagnato A
Cancer Res; 2003 May; 63(10):2447-53. PubMed ID: 12750265
[TBL] [Abstract][Full Text] [Related]
11. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R
Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140
[TBL] [Abstract][Full Text] [Related]
12. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
[TBL] [Abstract][Full Text] [Related]
14. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.
Mabuchi S; Terai Y; Morishige K; Tanabe-Kimura A; Sasaki H; Kanemura M; Tsunetoh S; Tanaka Y; Sakata M; Burger RA; Kimura T; Ohmichi M
Clin Cancer Res; 2008 Dec; 14(23):7781-9. PubMed ID: 19047105
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.
Hu L; Hofmann J; Holash J; Yancopoulos GD; Sood AK; Jaffe RB
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6966-71. PubMed ID: 16203789
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer.
Shah DK; Veith J; Bernacki RJ; Balthasar JP
Cancer Chemother Pharmacol; 2011 Oct; 68(4):951-8. PubMed ID: 21305289
[TBL] [Abstract][Full Text] [Related]
18. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
Klos KS; Zhou X; Lee S; Zhang L; Yang W; Nagata Y; Yu D
Cancer; 2003 Oct; 98(7):1377-85. PubMed ID: 14508823
[TBL] [Abstract][Full Text] [Related]
19. Combined effects of soluble vascular endothelial growth factor receptor FLT-1 gene therapy and cisplatin chemotherapy in human tongue carcinoma xenografts.
Gao ZN; Wei YQ; Yang PS; Xu X; Zhao HQ; Huan X; Kang B
Oral Oncol; 2007 May; 43(5):477-83. PubMed ID: 16997614
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]